Quantum Ledger
Vol. III·Cohort Profile·Algorithmiq
Helsinki, Finland·Founded 2020·Private
Boulder · Colorado
Analyst note · Software / QEC

Algorithmiq Software / QEC

Most-funded quantum drug discovery software company — pivoting from generic chemistry to clinical pharma partnerships.

Most-funded quantum drug discovery software company — pivoting from generic chemistry to clinical pharma partnerships.

— Ledger Desk · analyst thesis

Bull case

upside

$15M Series A 2023 + €10M extension; Roche, AstraZeneca research partnerships; published quantum-error-mitigation work that runs on IBM hardware. Sabrina Maniscalco (Helsinki) anchors the science. Strong position as IBM Quantum chemistry partner.

Bear case

downside

Quantum chemistry advantage at scale is still 3–5 years away on real hardware; software-only companies have narrow moats once hardware vendors internalize chemistry stacks. Revenue not publicly disclosed.

A profile is a snapshot of an argument, not a verdict. The Ledger updates the score nightly; the thesis we revisit only when the facts change.

— analyst-note conventions